1.Clinical Value of Platelet Distribution Width Ratio and Neutrophil Lymphocyte Ratio in the Evaluation of Coronary No-Reflow in Patients Treated by Emergency PCI
Linxia SUN ; Min MA ; Lamei JIN ; Qionghua SHE ; Juan YAN ; Yong HE
Progress in Modern Biomedicine 2017;17(25):4856-4859,4868
Objective:To investigate the clinical value ofplatelet distribution width ratio (RDW) and neutrophil lymphocyte ratio (NLR) in the prediction of coronary no reflow in patients treated with acute percutaneous coronary intervention (PCI).Methods:66 patients underwent emergency PCI treatment in our hospital from January 2016 December 2016 were selected as the research object,RDW and NLR of the patients before treatment were detected,and coronary no reflow phenomenon after emergency PCI rate were statistically calculated.RDW and NLR of patients with no reflow and normal blood flow were compared,the relationship between RDW and NLR with no reflow and the value of them predicting coronary no reflow were analyzed.Results:The incidence of coronary no reflow after emergency PCI was 30.30% (20/66).Compared with patients with normal blood flow,the RDW and NLR of patients with coronary no reflow were elevate (P<0.05).Spearman correlation analysis results showed that RDW and NLR were positively correlated with coronary no reflow (r=0.826,0.878,P<0.05).Further ROC curve analysis showed that AUC of preoperative RDW combined with NLR predicting the postoperative coronary no reflow in patients treated with emergency PCI were higher than RDW and NLR alone.Conclusion:RDW and NLR in patients treated with emergency PCI were closely related to the postoperative coronary no reflow,which might be used as reference index for evaluation of coronary no reflow after emergency PCI.
2.Pharmaceutical Care for a Case of ESBLs Producing Klebsiella pneumoniae Severe Pneumonia
Qionghua SUN ; Yaqing LYU ; Wencan ZHENG
China Pharmacy 2018;29(3):378-382
OBJECTIVE: To probe the role of clinical pharmacists in drug use of patients with severe pneumonia. METHODS: Clinical pharmacists participated in the treatment for a patient with ESBLs producing Klebsiella pneumoniae severe pneumonia. The patient was given cefoperazone tazobactam combined with moxifloxacin and ganciclovir initially. Clinical pharmacists suggested stopping cefoperazone tazobactam and moxifloxacin and additionally using meropenem according to the elevation of hemogram infection indexes; suggested stopping ganciclovir and continuously using meropenem according to the results of sputum culture; suggested providing cefoperazone sulbactam de-escalation sequential therapy for ESBLs producing Klebsiella pneumoniae and stopping cefoperazone sulbactam and azithromycin according to clinical symptoms of the patient. RESULTS: The physicians adopted the suggestions of clinical pharmacists. After treatment, body temperature and lab indexes of the patient recovered to normal; the result of sputum culture turned to negative. Chest CT showed that the infection focus was obviously absorbed compared to before. After discharged from hospital and followed up, the patient was found to have a good prognosis. CONCLUSIONS: Through actively participating in drug therapy, based on lab indexes and results of sputum culture, clinical pharmacists provide pharmaceutical care and adjust medication plan to improve treatment rate of patients with severe pneumonia and the safety and effectiveness of drug treatment, be of great significance to promote the rational use of antibiotics.
3.CCGD-ESCC: A Comprehensive Database for Genetic Variants Associated with Esophageal Squamous Cell Carcinoma in Chinese Population.
Linna PENG ; Sijin CHENG ; Yuan LIN ; Qionghua CUI ; Yingying LUO ; Jiahui CHU ; Mingming SHAO ; Wenyi FAN ; Yamei CHEN ; Ai LIN ; Yiyi XI ; Yanxia SUN ; Lei ZHANG ; Chao ZHANG ; Wen TAN ; Ge GAO ; Chen WU ; Dongxin LIN
Genomics, Proteomics & Bioinformatics 2018;16(4):262-268
Esophageal squamous-cell carcinoma (ESCC) is one of the most lethal malignancies in the world and occurs at particularly higher frequency in China. While several genome-wide association studies (GWAS) of germline variants and whole-genome or whole-exome sequencing studies of somatic mutations in ESCC have been published, there is no comprehensive database publically available for this cancer. Here, we developed the Chinese Cancer Genomic Database-Esophageal Squamous Cell Carcinoma (CCGD-ESCC) database, which contains the associations of 69,593 single nucleotide polymorphisms (SNPs) with ESCC risk in 2022 cases and 2039 controls, survival time of 1006 ESCC patients (survival GWAS) and gene expression (expression quantitative trait loci, eQTL) in 94 ESCC patients. Moreover, this database also provides the associations between 8833 somatic mutations and survival time in 675 ESCC patients. Our user-friendly database is a resource useful for biologists and oncologists not only in identifying the associations of genetic variants or somatic mutations with the development and progression of ESCC but also in studying the underlying mechanisms for tumorigenesis of the cancer. CCGD-ESCC is freely accessible at http://db.cbi.pku.edu.cn/ccgd/ESCCdb.
Aged
;
Asian Continental Ancestry Group
;
genetics
;
China
;
epidemiology
;
Databases, Genetic
;
Esophageal Squamous Cell Carcinoma
;
genetics
;
Female
;
Genetic Predisposition to Disease
;
Genetic Variation
;
Genome-Wide Association Study
;
Humans
;
Internet
;
Male
;
Middle Aged
;
Polymorphism, Single Nucleotide
;
genetics
;
User-Computer Interface